|
FOR US RESIDENTS ONLY
|
CML Therapy Support
For Patients and
Caregivers
Building on a 5-year legacy of improvement in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Novartis Oncology introduces CML Alliance, a unique support program designed to help optimize outcomes in Ph+ CML patients.
What is CML?
CML (chronic myeloid leukemia or chronic myelogenous leukemia) is a cancer of the blood and bone marrow (soft tissue within bones). Blood cells are made in the bone marrow.
How is CML Treated?
Chronic myelogenous leukemia (CML) is caused by a mutation that makes abnormal blood cells multiply and crowd out healthy ones. Treatment may block the signal that causes this growth.
The Importance of Staying on Course: Taking Your Treatment as Prescribed
Staying the course with daily treatment can be difficult, even when you know that it is important for your health. Fortunately, there are things that you can do to help yourself stay on track.
Ph+ CML patients
Use of this website is governed by the
Terms of Use
and
Privacy Statement
.
Copyright 2009 Novartis Pharmaceuticals Corporation. All Rights Reserved.
|